GlaxoSmithKline plc (NYSE:GSK) saw an upside of 1.44% to $38.79 after adding $0.55 on Tuesday. The 5-day average trading volume is 3,768,973 shares of the company’s common stock. It has gained $39.26 in the past week. An average of 3,740,863 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,459,415.
GSK’s 1-month performance is -3.80% or -$0.95 on its low of $37.80 reached on 10/06/21. The company’s shares have touched a 52-week low of $33.26 and high of $42.68, with the stock’s rally to the 52-week high happening on 08/18/21. YTD, GSK has achieved 3.91% or $2.00. However, the current price is down -9.11%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On May 20, 145 days have gone by since the last insider trading activity for GlaxoSmithKline plc (GSK). GLAXOSMITHKLINE PLC (10% Owner) most recently sold 32,005,260 shares at $12.25 per share on May 20. This transaction cost the insider $392,064,435.
The company’s PE ratio for the last five years has touched a high of 354.72 and a low of 10.37. GSK stock has a beta of 0.68. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2.11 while the price-to-book (PB) in the most recent quarter is 4.57, with the price to cash flow ratio at 62.90.
GlaxoSmithKline plc pays an annual dividend of $2.04 per share. Its dividend yield is 5.26% and the payout ratio is 50.90%. GSK’s most recent quarterly dividend payment was made on Oct. 7, when it paid $0.5230 a share compared with prior rate of $0.6367, down -21.74% from last year’s. The company latest dividend decrease of $0.1137 reported on Friday July 30 2021. Measured over the last 3 years, the Dividend has been growing by -1.26% yearly.
It is projected that GlaxoSmithKline plc’s next ex-dividend date will be on 15-Nov. GSK is expected to distribute $0.482 as its next dividend.
GlaxoSmithKline plc’s quick ratio for the period ended June 29 was 0.50, with the current ratio over the same period at 0.80 meaning that GSK stock is not able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 1.33, while the total debt to equity was 1.66. In terms of profitability, the gross margin trailing 12 months is 67.70%. The trailing 12-month EBITDA margin is 30.89% while for the period ending June 29; GlaxoSmithKline plc’s operating margin was 19.10%. The firm’s gross profit as reported stood at $28.76 billion against revenue of $43.78 billion.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected GSK to announce $0.51 per share in earnings in its latest quarter, but it posted $0.79, representing a 54.90% surprise. EBITDA for the quarter stood at more than $3.28 billion. GSK stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 77.48 billion, with total debt at $25.48 billion
Let’s look briefly at GlaxoSmithKline plc (GSK) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 51.99% to suggest the stock is trending Neutral, with historical volatility in this time period at 13.28%.
The stock’s 5-day moving average is $38.51, reflecting a +1.52% or $0.58 change from its current price. GSK is currently trading -1.45% above its 20-day SMA, -0.59% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -3.58% and +7.36% respectively.
Stochastic %K and %D was 42.78% and 40.15% and the average true range (ATR) pointed at 0.53. The RSI (14) points at 47.06%, while the 14-day stochastic is at 55.35% with the period’s ATR at 0.51. The stock’s 9-day MACD Oscillator is pointing at 0.19 and 0.15 on the 14-day charts.
In the most recent analyst report for GlaxoSmithKline plc (NYSE: GSK), Deutsche Bank upgraded it to a Hold rating. They previously had a Sell rating on the stock. Analysts offering their rating for GSK stock have a consensus rating for the stock as Overweight. Currently, 2 brokerage advisors rate GSK as a “sell,”, while 12 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 2 rates the stock as overweight while 8 have offered a “buy” rating.
What is GSK’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $37.41 and a high of $57.38, with their median price target at $42.37. Looking at these predictions, the average price target given by analysts is for GlaxoSmithKline plc (GSK) stock is $44.13.